Avibela Archives - Medicines360

Medicines360 Commemorates World Contraception Day 2019

As Medicines360 commemorates World Contraception Day 2019, we recognize the work we’ve done and the work we have left to do. Too many women in the U.S. and across the globe still have difficulty accessing the full range of contraceptive options to live their lives on their own terms. In addition to improving contraceptive access […]

Medicines360 Welcomes Margot Fahnestock as Vice President of Strategic Development

Medicines360 is delighted to announce that Margot Fahnestock has joined our team as Vice President of Strategic Development. Margot will be responsible for planning, organizing, and implementing all of our high-impact strategic programming and fundraising efforts both in the U.S. and globally. Before Medicines360, Margot served as a Program Officer in the William and Flora […]

AVIBELA™ Launches in Zambia

Medicines360 is excited to announce that Avibela™, our 52 mg levonorgestrel intrauterine device (IUD), has launched in Zambia! AVIBELA is the first hormonal IUD registered in Zambia. AVIBELA is not indicated for use in the United States. Through the global FP2020 initiative, the Zambian government has committed to improving sustainable access to family planning. In alignment […]

Medicines360 Announces Collaborative Research to Increase LARC Access in FQHCs

Federally Qualified Health Centers (FQHCs) are community-based providers that exist to meet patients where they live and provide the primary care services they need. With approximately 12,000 service delivery sites located across the country. FQHCs serve a large number of both insured and uninsured patients. FQHCs have sliding fee scales for uninsured patients to make […]

©2022 Medicines360. A 501(c)(3) tax-exempt organization. Medicines360® and its design are registered trademarks of Medicines360.

Avibela® is a registered trademark of Medicines360 in countries across Africa, South and Southeast Asia, Central America, and the Caribbean.

Impact RH360® is a registered trademark of Medicines360 in Madagascar, Rwanda, Uganda, South Africa, and Zambia.

All other trademarks are property of their respective owners.

Tina Raine-Bennett, MD, MPH, FACOG

Chief Executive Officer

Tina Raine-Bennett, MD, MPH, is CEO of Medicines360. Previously, she served as a senior research scientist at the Kaiser Permanente Northern California Division of Research and the research director of the Women’s Health Research Institute. She is a Board-Certified Obstetrician Gynecologist who received her medical training at the University of California, San Diego, and post-graduate residency training and MPH at the University of Washington in Seattle, where she also completed a Robert Wood Johnson Clinical Scholars Fellowship. She was also senior staff physician at Kaiser Permanente and has a special interest in family planning and adolescent reproductive health.

As the director of the Women’s Health Research Institute, Dr. Raine-Bennett focused on expanding research on women’s health within the Division and translating women’s health research into clinical practice and policy within the Ob/Gyn departments in Northern California. She also promoted the involvement of clinicians in research designed to improve the health outcomes and healthcare experiences of women at Kaiser Permanente and women in general.

Prior to Kaiser Permanente, Dr. Raine-Bennett was a professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at University of California, San Francisco (UCSF). She was based at San Francisco General Hospital where she was also the medical director of the New Generation Health Center, a UCSF affiliate site that provides community-based reproductive health services. Dr. Raine-Bennett’s research has focused on contraceptive methods and on elucidating factors that influence contraceptive choice and continuation, and she was principal investigator on NIH grants to assess hormonal contraceptive use predictors and develop interventions to improve contraceptive access.

Her past and current research on emergency contraception has focused on the safety of making emergency contraception more accessible and she conducted a pivotal clinical trial to make emergency contraception available to teens without a prescription. She served on the editorial board of Obstetrics and Gynecology and has over 100 peer-reviewed publications. She was the Treasurer of the Board of Directors for the Society of Family Planning and Society of Family Planning Research Fund. She has also served as an examiner for the American Board of Obstetrics and Gynecology, and on national committees for the American College of Obstetrics and Gynecology and the National Medical Board of Planned Parenthood Federation of America.